TRVI
Closed
Trevi Therapeutics Inc
6.6
-0.1 (-1.50%)
Last Update: 08 May 2025 23:00:00
Yesterday: 6.66
Day's Range: 6.37 - 6.78
Send
sign up or login to leave a comment!
When Written:
1.83
Trevi Therapeutics Inc. is a clinical-stage biopharmaceutical company that is focused on developing therapies for patients suffering from rare neurological disorders. The company's lead product candidate, Nalbuphine ER, is a long-acting oral formulation of nalbuphine, a potent opioid analgesic that has been used for decades in the management of acute and chronic pain.
Trevi Therapeutics was founded in 2011 and is headquartered in New Haven, Connecticut. The company is led by a team of experienced industry executives and has partnerships with leading academic institutions and research organizations.
In addition to Nalbuphine ER, Trevi Therapeutics is also exploring the potential of other compounds in its pipeline for the treatment of various neurological disorders. These include TRV250, a novel delta opioid receptor agonist for the treatment of acute migraine, and TRV734, a G protein-biased mu opioid receptor agonist for the treatment of chronic pain.
Trevi Therapeutics has received funding from a variety of sources, including venture capital firms and government agencies. The company went public in 2019 and is listed on the NASDAQ stock exchange under the ticker symbol TRVI.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Trevi Therapeutics was founded in 2011 and is headquartered in New Haven, Connecticut. The company is led by a team of experienced industry executives and has partnerships with leading academic institutions and research organizations.
In addition to Nalbuphine ER, Trevi Therapeutics is also exploring the potential of other compounds in its pipeline for the treatment of various neurological disorders. These include TRV250, a novel delta opioid receptor agonist for the treatment of acute migraine, and TRV734, a G protein-biased mu opioid receptor agonist for the treatment of chronic pain.
Trevi Therapeutics has received funding from a variety of sources, including venture capital firms and government agencies. The company went public in 2019 and is listed on the NASDAQ stock exchange under the ticker symbol TRVI.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!